CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
May 2015—Thermo Fisher Scientific and Samsung Electronics have formed a strategic collaboration to jointly design, develop, and market new point-of-care solutions in key applications, such as the detection of sepsis, drugs of abuse, and therapeutic drug monitoring as well as the detection of cardiac problems and women’s health conditions.
“Samsung has developed a compelling and innovative suite of POC platforms,” said Marc Tremblay, PhD, president of Thermo Fisher’s clinical diagnostics business. “We look forward to working with Samsung to add some of our leading biomarkers and assays to their platforms to create a truly differentiated testing menu.”
Thermo Fisher Scientific, 781-622-1000